What is Zacks Research’s Forecast for GSK FY2024 Earnings?

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research raised their FY2024 earnings estimates for shares of GSK in a report issued on Tuesday, November 19th. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will post earnings of $4.12 per share for the year, up from their previous forecast of $4.11. The consensus estimate for GSK’s current full-year earnings is $4.03 per share. Zacks Research also issued estimates for GSK’s Q1 2026 earnings at $1.14 EPS and Q3 2026 earnings at $1.57 EPS.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Seven analysts have rated the stock with a hold rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Up 1.0 %

Shares of NYSE GSK opened at $33.67 on Friday. GSK has a 12-month low of $32.83 and a 12-month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a market cap of $69.79 billion, a PE ratio of 21.87, a P/E/G ratio of 1.29 and a beta of 0.66. The company’s fifty day simple moving average is $38.27 and its 200 day simple moving average is $40.44.

Institutional Trading of GSK

A number of large investors have recently bought and sold shares of the company. Natixis Advisors LLC lifted its holdings in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after purchasing an additional 83,433 shares in the last quarter. Van ECK Associates Corp grew its stake in GSK by 8.4% during the third quarter. Van ECK Associates Corp now owns 736,510 shares of the pharmaceutical company’s stock valued at $27,973,000 after acquiring an additional 56,843 shares in the last quarter. Cohen Investment Advisors LLC purchased a new position in GSK in the second quarter worth $349,000. Equity Investment Corp increased its stake in GSK by 1.8% in the third quarter. Equity Investment Corp now owns 3,496,254 shares of the pharmaceutical company’s stock valued at $142,927,000 after acquiring an additional 63,052 shares during the last quarter. Finally, Stockman Wealth Management Inc. raised its position in GSK by 7.7% during the third quarter. Stockman Wealth Management Inc. now owns 209,517 shares of the pharmaceutical company’s stock valued at $8,565,000 after purchasing an additional 15,024 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of GSK stock in a transaction dated Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.00% of the stock is currently owned by company insiders.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a $0.3928 dividend. The ex-dividend date is Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.67%. GSK’s dividend payout ratio is currently 98.70%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.